Do statins increase HbA1c? This is a clinically important question for the millions of people prescribed these cholesterol-lowering medicines across the UK. Statins are a cornerstone of cardiovascular prevention, yet evidence over the past decade has consistently shown they can modestly raise blood glucose levels and HbA1c — the marker used to diagnose and monitor type 2 diabetes. Understanding the magnitude of this effect, who is most at risk, and how to monitor it appropriately is essential for patients and clinicians alike. This article explains the evidence, outlines relevant NICE and NHS guidance, and helps you weigh the cardiovascular benefits against the metabolic risks.

How Statins May Affect Blood Glucose and HbA1c Levels

Statins may raise blood glucose and HbA1c through impaired insulin secretion, increased insulin resistance, and reduced peripheral glucose uptake, with hyperglycaemia listed as a recognised adverse effect in UK-licensed statin SmPCs.

Experiencing these side effects? Our pharmacists can help you navigate them →

Statins are among the most widely prescribed medicines in the UK, used primarily to lower low-density lipoprotein (LDL) cholesterol and reduce the risk of cardiovascular events such as heart attack and stroke. However, research over the past decade has raised questions about whether statins may also influence blood glucose regulation — and, by extension, HbA1c levels.

HbA1c (glycated haemoglobin) is a marker that reflects average blood glucose concentrations over the preceding two to three months. It is reported in the UK in mmol/mol units (for example, a level of 48 mmol/mol corresponds to approximately 6.5% in older percentage units). HbA1c is used both to diagnose type 2 diabetes and to monitor glycaemic control in people already living with the condition. Even modest increases can be clinically meaningful, particularly in individuals who are already at risk of developing diabetes.

Several mechanisms have been proposed — though not definitively established — by which statins may raise blood glucose:

• Impaired insulin secretion — statins may reduce calcium uptake into pancreatic beta cells, which is essential for triggering insulin release

• Increased insulin resistance — some evidence suggests statins may interfere with glucose transporter type 4 (GLUT-4) signalling in muscle and adipose tissue, reducing the body's sensitivity to insulin

• Reduced peripheral glucose uptake — statins may impair the ability of peripheral tissues to absorb glucose from the bloodstream

These proposed mechanisms are based on experimental and observational data and remain an active area of investigation (Sattar et al., The Lancet, 2010; mechanistic reviews including Nakata et al.). The degree of impact appears to vary depending on the specific statin used, the dose, and individual patient characteristics. Notably, some evidence suggests that pravastatin may carry a lower risk of glucose dysregulation than higher-intensity agents such as atorvastatin or rosuvastatin, though this requires further confirmation. The summary of product characteristics (SmPC) for atorvastatin and rosuvastatin, available via the electronic Medicines Compendium (eMC), lists hyperglycaemia and increased HbA1c as recognised adverse effects.

What the Clinical Evidence Says About Statins and HbA1c

Statins raise HbA1c by approximately 1–3 mmol/mol on average and increase the relative risk of new-onset type 2 diabetes by around 9%, with high-intensity regimens carrying greater risk than lower-intensity ones.

The association between statin use and elevated HbA1c has been supported by several large-scale studies and meta-analyses. A landmark 2010 meta-analysis published in The Lancet (Sattar et al.), which analysed data from 13 randomised controlled trials involving over 91,000 participants, found that statin therapy was associated with a 9% increased relative risk of incident type 2 diabetes. Subsequent studies have broadly confirmed this finding.

In terms of HbA1c specifically, published meta-analyses suggest that statins can raise HbA1c by approximately 0.1 to 0.3 percentage points (roughly 1 to 3 mmol/mol) on average. Whilst this may appear small, it can be sufficient to shift some individuals from a non-diabetic hyperglycaemia range into a diabetic one, particularly those with existing metabolic risk factors.

A further meta-analysis (Preiss et al., JAMA, 2011) demonstrated that intensive-dose statin therapy was associated with a significantly higher risk of new-onset diabetes compared with moderate-dose therapy. High-intensity statins — such as atorvastatin 40–80 mg and rosuvastatin 20–40 mg — therefore appear to carry a somewhat greater risk than lower-intensity agents such as pravastatin or fluvastatin.

Data from the Cholesterol Treatment Trialists' (CTT) Collaboration provide important context: for every 1 mmol/L reduction in LDL cholesterol, statin therapy reduces the risk of major vascular events by approximately 21–22%, with absolute benefits scaling with baseline cardiovascular risk. This underscores that the cardiovascular gains from statin therapy substantially outweigh the modest increase in diabetes risk for most patients.

Overall, the evidence supports a real, if modest, effect of statins on HbA1c and diabetes risk. This does not mean statins should be avoided, but it does underscore the importance of appropriate monitoring and patient counselling.

Who Is Most at Risk of HbA1c Changes on Statin Therapy

People with non-diabetic hyperglycaemia, metabolic syndrome, older age, higher BMI, or a family history of type 2 diabetes are at greatest risk of clinically significant HbA1c elevation on statin therapy.

Not everyone who takes a statin will experience a meaningful rise in HbA1c or go on to develop type 2 diabetes. The risk is concentrated in individuals who already have underlying metabolic vulnerability. Understanding who is most susceptible helps clinicians and patients make informed, shared decisions about treatment.

Those at greatest risk of statin-associated HbA1c elevation include:

• People with non-diabetic hyperglycaemia (NDH) — also commonly referred to as pre-diabetes — defined in the UK as an HbA1c of 42–47 mmol/mol or a fasting plasma glucose of 5.5–6.9 mmol/L (NHS Diabetes Prevention Programme eligibility criteria, UKHSA/PHE). These individuals are already close to the diagnostic threshold for type 2 diabetes

• Individuals with metabolic syndrome — characterised by central obesity, hypertension, dyslipidaemia, and impaired fasting glucose

• Older adults, particularly those aged over 65, who may have reduced beta-cell reserve

• People with a higher body mass index (BMI), especially those with significant visceral adiposity

• Those with a family history of type 2 diabetes

• Patients on higher doses of high-intensity statins, such as atorvastatin 80 mg or rosuvastatin 40 mg (Preiss et al., JAMA, 2011)

Conversely, individuals who are metabolically healthy, have a normal BMI, and have no personal or family history of diabetes are at considerably lower absolute risk of a clinically significant HbA1c change.

It is also worth noting that lifestyle factors — including physical inactivity, poor diet, and smoking — interact with statin use and may amplify any underlying tendency towards glucose dysregulation. Addressing these modifiable risk factors remains an important part of holistic cardiovascular and metabolic care.

NICE and NHS Guidance on Monitoring Diabetes Risk With Statins

NICE NG238 recommends checking baseline HbA1c or fasting plasma glucose before starting statins in at-risk individuals, with annual HbA1c review for those with non-diabetic hyperglycaemia commenced on statin therapy.

NICE guideline NG238 (Cardiovascular disease: risk assessment and reduction, including lipid modification, 2023 — which replaces the earlier CG181) acknowledges the association between statin therapy and a small increased risk of developing type 2 diabetes. Clinicians are advised to inform patients of this risk as part of the shared decision-making process before initiating statin therapy.

In terms of monitoring, NICE NG238 recommends that HbA1c or fasting plasma glucose should be checked before starting a statin in patients who are at risk of diabetes (i.e., those with non-diabetic hyperglycaemia or other metabolic risk factors), and that ongoing monitoring should be considered in line with standard diabetes prevention pathways. Routine glucose monitoring is not required for all statin users — it is targeted at those with identified risk.

Key monitoring recommendations aligned with NICE NG238 and BNF guidance include:

• Baseline HbA1c or fasting plasma glucose prior to statin initiation in at-risk individuals

• Annual HbA1c review for patients with non-diabetic hyperglycaemia (NDH) who are commenced on statin therapy

• Lipid profile and liver enzymes (LFTs) at baseline, at approximately 3 months after starting treatment, and again at 12 months; thereafter only if clinically indicated

• Lipid response target: NICE NG238 recommends aiming for a reduction of ≥40% in non-HDL cholesterol from baseline at approximately 3 months; if this is not achieved, adherence and dose optimisation should be reviewed

• Creatine kinase (CK) should be measured if a patient develops muscle symptoms (myalgia, weakness); routine CK monitoring is not recommended

• Blood pressure and weight as part of broader cardiovascular risk management

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Drug Safety Update confirming that the risk of hyperglycaemia and new-onset diabetes with statins is a recognised class effect. This information is included in the patient information leaflets and SmPCs for all statin medicines licensed in the UK (available via the eMC). Patients should be encouraged to read this information and raise any concerns with their GP or pharmacist.

Patients and healthcare professionals are also encouraged to report suspected adverse effects — including unexpected changes in blood glucose — via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or using the Yellow Card app.

Weighing the Cardiovascular Benefits Against Diabetes Risk

For most patients, statins' cardiovascular benefits substantially outweigh the modest diabetes risk; approximately one additional diabetes case occurs per 255 patients treated over four years, whilst multiple major cardiovascular events are prevented.

It is essential to contextualise the modest risk of HbA1c elevation within the broader picture of what statins achieve. For the vast majority of patients — particularly those with established cardiovascular disease or a 10-year cardiovascular risk of 10% or more — the benefits of statin therapy substantially outweigh the risk of a small increase in blood glucose, as affirmed by NICE NG238.

Data from the Cholesterol Treatment Trialists' (CTT) Collaboration demonstrate that statins significantly reduce the risk of major cardiovascular events, including myocardial infarction, stroke, and cardiovascular death, with absolute benefits scaling with baseline risk. In high-risk populations, this translates to preventing a substantial number of premature deaths and serious events annually across the UK.

A useful way to frame the absolute trade-off for patients is as follows (based on Sattar et al., The Lancet, 2010, and CTT data; figures are approximate and vary by baseline risk and statin intensity):

• For approximately every 255 patients treated with a statin for four years, roughly one additional case of diabetes may occur

• Over the same period, in a high-risk population, statins may prevent five or more major cardiovascular events per 255 patients treated

These figures are illustrative and context-dependent — the absolute benefit is greater in those with higher baseline cardiovascular risk (e.g., established heart disease or prior stroke) and with higher-intensity statin regimens, whilst the absolute diabetes risk is most relevant in those with pre-existing metabolic vulnerability.

For individuals at lower cardiovascular risk — such as those being considered for primary prevention with a 10-year risk below 10% — the benefit-risk calculation is more nuanced, and shared decision-making becomes especially important. In these cases, lifestyle modification, including dietary changes and increased physical activity, may be prioritised before or alongside statin therapy.

The key message is that statins remain a cornerstone of cardiovascular prevention in the UK, and concerns about HbA1c should inform monitoring and lifestyle support — not lead to unnecessary discontinuation of treatment.

When to Speak to Your GP About Statins and Blood Sugar

Contact your GP if you develop symptoms of hyperglycaemia, notice a rising HbA1c since starting a statin, or are newly diagnosed with non-diabetic hyperglycaemia — do not stop statin therapy without medical advice.

If you are taking a statin and have concerns about your blood sugar levels or HbA1c, it is important to raise these with your GP or practice nurse rather than stopping your medication without medical advice. Abruptly discontinuing statin therapy can significantly increase your cardiovascular risk, particularly if you have established heart disease or have previously had a stroke.

You should contact your GP if you notice any of the following:

• Increased thirst or frequent urination, which may suggest elevated blood glucose

• Unexplained fatigue or blurred vision, which can be associated with hyperglycaemia

• A recent HbA1c result that has risen since starting or increasing your statin dose

• You have been newly diagnosed with non-diabetic hyperglycaemia (NDH) and are already on statin therapy

• You are concerned about your overall diabetes risk and would like a formal assessment

If you experience symptoms that may suggest markedly elevated blood glucose — such as severe thirst, vomiting, confusion, or drowsiness — seek urgent medical attention or contact NHS 111.

Your GP may arrange a repeat HbA1c test, review your statin dose, or consider switching to a lower-intensity statin if clinically appropriate. They may also refer you to the NHS Diabetes Prevention Programme (Healthier You), a free evidence-based lifestyle intervention available in England for those at high risk of developing type 2 diabetes (HbA1c 42–47 mmol/mol or fasting plasma glucose 5.5–6.9 mmol/L). If you live in Wales or Scotland, equivalent programmes are available through your local NHS; please ask your GP or practice nurse about services in your area.

It is worth remembering that lifestyle changes — including a balanced diet, regular physical activity, maintaining a healthy weight, and reducing alcohol intake — can meaningfully reduce the risk of statin-associated glucose dysregulation. These measures complement, rather than replace, your prescribed medication. Always discuss any changes to your treatment with a qualified healthcare professional.

If you believe you have experienced a side effect from your statin, you can report it directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or using the Yellow Card app.

Frequently Asked Questions